Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07478731RecruitingPhase 2
Combination therapy for advanced rectal cancer before surgery
This trial tests a new drug called SHR-1701 combined with standard chemotherapy and radiation for people with locally advanced rectal cancer. The goal is to shrink the tumor before surgery, making it easier to remove completely.
Wuhan, HubeiAges 18–75 - NCT07482566Recruiting
Comparing two surgeries for advanced gastroesophageal junction cancer
This trial compares two types of stomach-removing surgeries (total vs. partial gastrectomy) in people with a certain kind of advanced gastroesophageal junction cancer. The goal is to find out which surgery leads to better outcomes.
Istanbul, IstanbulAges 18–90 - NCT07532902RecruitingPhase 1
Testing an experimental drug with standard care for solid tumors
This trial tests a new drug (BMS-986504) combined with standard chemotherapy or immunotherapy for three types of advanced solid tumors: mesothelioma, gastroesophageal cancer, or bladder cancer. It may be an option if your tumor has a specific genetic change called MTAP deletion.
Basking Ridge, New JerseyAges 18 years+ - NCT06747585RecruitingPhase 1/Phase 2
ALE.P02 for advanced squamous cell cancers with CLDN1
This trial tests a new drug called ALE.P02 for people with advanced squamous cell cancers (like lung, head and neck, esophagus, or skin cancer) that have a certain protein called CLDN1. The drug is given alone and aims to shrink or stop the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT05377996RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with tumor tissue testing
This early-stage study tests emiltatug leda-dotin (Emi-Le) in people with advanced or recurring solid cancers. It aims to see how the drug works and how safely it can be given, using tumor tissue testing to help understand who may benefit.
Phoenix, ArizonaAges 18 years+ - NCT07504796RecruitingPhase 4
Adding ipilimumab to standard melanoma therapy based on ctDNA
This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.
New York, New YorkAges 18 years+ - NCT07511413Recruiting
Monitoring health in head, neck, lung & rectal cancer
This trial is studying how a monitoring method (bioimpedance) works for people with head and neck, lung, or rectal cancer who are about to start standard treatment. It may help doctors track your health better during therapy.
Candiolo, Torino (TO)Ages 18 years+ - NCT07514754Recruiting
Immunonutrition support during cancer treatment
This study tests whether special nutritional support (called immunonutrition) helps patients with head and neck, lung, or rectal cancer who are receiving chemotherapy, radiation, or immunotherapy. The goal is to see if it improves how well treatment works and how you feel during and after cancer care.
Candiolo, Torino (TO)Ages 18 years+ - NCT07528209RecruitingPhase 3
Chemotherapy with or without immunotherapy for advanced rectal cancer
This study tests whether adding an immunotherapy drug (pucotenlimab) to standard chemotherapy (CAPOX) before surgery helps treat locally advanced rectal cancer better. The goal is to shrink tumors and improve survival while preserving bowel function when possible.
Guangzhou, GuangdongAges 18–75 - NCT07559045RecruitingPhase 2
Chemo-Immunotherapy Plus Radiation vs Standard Treatment for Advanced Esophageal Cancer
This trial compares two treatment approaches for advanced esophageal squamous cell carcinoma (a type of cancer that starts in the lining of the food tube). One group receives chemotherapy combined with an immunotherapy drug before radiation; the other receives chemotherapy and radiation at the same time. The goal is to see which approach works better.
Zunyi, GuizhouAges 18–75 - NCT07594925RecruitingPhase 2
Short-course radiation plus immunotherapy and chemotherapy for rectal cancer
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
TianjinAges 18–75 - NCT07595835RecruitingPhase 1/Phase 2
Radioactive particles injected into pancreatic tumors
This trial tests a new treatment where doctors use imaging to guide radioactive particles directly into locally advanced pancreatic cancer tumors that haven't spread. The goal is to shrink or control the cancer with radiation delivered right to the tumor.
Amsterdam, North HollandAges 18 years+ - NCT07627334Recruiting
Personalized drug testing for newly diagnosed brain tumors
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
Vienna, State of ViennaAges Any age - NCT07638436RecruitingPhase 2
Immunotherapy with chemotherapy for advanced esophageal cancer
This trial tests whether combining a new immunotherapy drug (adebrelimab) with standard chemotherapy can help shrink borderline resectable esophageal squamous cell carcinoma before surgery. The goal is to make tumors easier to remove and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT07646106RecruitingPhase 1
Testing THE-0504 in Advanced Solid Tumors
This Phase 1 trial tests a new drug called THE-0504 in patients with advanced solid tumors (like lung, colon, pancreas, stomach, or breast cancer) that have not responded to standard treatments. The study aims to find the right dose and understand how well and safely the drug works.
Rome, LazioAges 18 years+ - NCT07655024RecruitingPhase 2
TAIC plus FOLFOX for advanced stomach cancer
This trial tests a traditional Chinese medicine (TAIC) combined with chemotherapy (FOLFOX) for people with advanced stomach or gastroesophageal junction cancer that can't be removed with surgery. It aims to see if the combination can help shrink the tumor and improve survival.
BeijingAges 18 years+ - NCT07664579Recruiting
Couples coping together against cancer support program
This trial tests a supportive care program for couples facing cancer. It helps you and your partner work together to manage the challenges of a cancer diagnosis.
Duarte, CaliforniaAges 18 years+ - NCT07567716Enrolling by invitation
Study of How Advanced Esophageal Cancer Spreads After Surgery
This research examines tissue samples from patients who had surgery to remove advanced esophageal cancer in the neck or chest area. The study aims to understand how the cancer invaded surrounding tissues, which may help doctors better treat similar patients in the future.
ShanghaiAges Any age - NCT07550972Enrolling by invitationPhase 2
Combination drug treatment before surgery for advanced head and neck cancer
This study tests two drugs (pertuzumab and lenvatinib) given together before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve outcomes for patients who haven't received prior cancer treatment.
Hangzhou, ZhejiangAges 18–75 - NCT07532928Enrolling by invitation
Personalized Post-Surgery Care Plan for Advanced Head and Neck Cancer
This study helps doctors create a personalized plan for follow-up treatment after surgery for advanced head and neck cancer. Researchers will use imaging scans and patient data to predict which patients need extra treatment and which ones can be monitored closely instead.
GuangzhouAges 18 years+ - NCT07371247Enrolling by invitationEarly Phase 1
Adjuvant treatment guided by ctDNA after chemoradiation for esophageal cancer
This trial tests whether adjusting treatment based on a blood test (ctDNA) after standard chemoradiation can improve outcomes for patients with advanced esophageal squamous cell carcinoma. It aims to find a more personalized approach to prevent cancer recurrence.
Nanjing, JiangsuAges 18–80 - NCT06890871Enrolling by invitationPhase 1/Phase 2
Radiation with immunotherapy and anti-angiogenic therapy for advanced HER2-negative breast cancer
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
Wuhan, HubeiAges 18–75 - NCT06883084Enrolling by invitation
How lymph node changes affect rectal cancer outcomes
This trial looks at how much the lymph nodes respond to chemoradiation before surgery in people with locally advanced rectal cancer. It aims to understand if that response can predict long-term results and guide future treatment choices.
Ages 18–65 - NCT06714084Enrolling by invitation
Treating high-risk cervical cancer with chemoradiation and immunotherapy
This trial tests a new drug called Cardenimumab combined with standard chemotherapy and radiation for women with high-risk cervical cancer. The goal is to see if adding this drug can improve outcomes for patients whose tumors are large, have spread to lymph nodes, or are stage IV.
Wuhan, HubeiAges 18–75
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,366 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.